MIV Therapeutics Inc (fka MIVI)

[stehvestor]

The potential of this stock outweighs the present cost. I think they are closer to human trial than I expected and Europe is ready for them.

The coating can reduce the effects of blood clots by 50%, check with the ir department to confirm that number and the cost of
our stent is about half of the going rate. The beauty is that this may control clotting after surgery. The application is bigger than first thought. Recently a neighbor of mine had a knee replaced. The operation was good. however he developed a blood clot and died.

Could our coating have helped him, I am not sure but it may have.